Medication info
OlmeTine Tablet 20/20 mg

OlmeTine Tablet 20/20 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
White or yellowish round film-coated tablets
Packaging
30 tablets/box [30 tablets (10 tablets/Alu-Alu) x 3]
Approval status
Active

MFDS item code 202003947 · Approved 2020.05.28

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil/rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase the dose to 20mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. The blood pressure-lowering effect occurs within 2 weeks after starting treatment and reaches its maximum effect at about 8 weeks. If blood pressure is not adequately controlled with this medicine alone, it may be administered concomitantly with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have intravascular volume depletion (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. 2. Elderly patients No dose adjustment is necessary when this medicine is administered to patients aged 65 years or older. 3. Patients with renal impairment The maximum dose in patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. The recommended initial dose in patients with moderate hepatic impairment is 10mg once daily, and the dose may be increased to a maximum of 20mg daily. Since there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL-cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL-cholesterol levels, the treatment goal, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment Although no increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination containing the same amounts of each active ingredient) for convenience of administration.
Child dose
The safety and efficacy in children under 18 years of age have not been established.

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol level
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is prescribed only for patients using the two drugs, Olmesartan Medoxomil and Rosuvastatin, together. Olmesartan Medoxomil is primarily effective for treating essential hypertension. Rosuvastatin is used for various dyslipidemic conditions, especially primary hypercholesterolemia and mixed dyslipidemia, and is used as an adjunct when diet and exercise do not suffice. It is also used in conjunction with dietary control for patients with homozygous familial hypercholesterolemia and dysbetalipoproteinemia. Rosuvastatin lowers total cholesterol and LDL cholesterol levels, slows the progression of atherosclerosis, and helps reduce the risks associated with cardiovascular diseases. In summary, this drug improves cardiovascular health by managing both hypertension and hyperlipidemia.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil/rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase the dose to 20mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. The blood pressure-lowering effect occurs within 2 weeks after starting treatment and reaches its maximum effect at about 8 weeks. If blood pressure is not adequately controlled with this medicine alone, it may be administered concomitantly with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have intravascular volume depletion (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. 2. Elderly patients No dose adjustment is necessary when this medicine is administered to patients aged 65 years or older. 3. Patients with renal impairment The maximum dose in patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. The recommended initial dose in patients with moderate hepatic impairment is 10mg once daily, and the dose may be increased to a maximum of 20mg daily. Since there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL-cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL-cholesterol levels, the treatment goal, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment Although no increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination containing the same amounts of each active ingredient) for convenience of administration.

Child dose

The safety and efficacy in children under 18 years of age have not been established.

Precautions

This medication can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. It should not be used in individuals with hypersensitivity to this medication, in pregnant or breastfeeding women, or in fertile women who are not using adequate contraception. This medication should not be administered to patients with certain health conditions such as severely impaired renal function or those undergoing dialysis, severe liver impairment, cholestasis, or myopathy. Hypotension may occur in patients with low blood volume or salt deficiency, so sufficient precursory checks and caution are necessary before administration, and regular monitoring is needed due to the potential for kidney function changes. Myalgias, myopathy, and, rarely, rhabdomyolysis may occur, so immediate medical attention is required if muscle-related symptoms occur. Liver function abnormalities have also been reported, and periodic liver enzyme testing is necessary; if signs of liver damage appear, administration should be stopped immediately. This medication can lower blood pressure, which may cause dizziness; caution should be used when driving or operating dangerous machinery. Drug interactions may occur with certain medications, so patients taking other drugs should inform their healthcare providers, especially with potassium-sparing diuretics, lithium, or non-steroidal anti-inflammatory drugs. Women who are pregnant or could become pregnant must use adequate contraception and should not use this medication during pregnancy. The safety and efficacy of this medication have not been established in children under 18 years old, so use is not recommended. In the elderly, dosing adjustments and monitoring may be necessary due to potential increases in drug concentration. Overdosage can lead to symptoms such as hypotension and palpitations; immediate medical treatment should be sought in such cases. This medication should be kept out of reach of children, and should not be transferred to other containers.

Side effects

Elevation of ALT, elevation of AST, increase in serum creatinine, decreased creatinine clearance, headache, dizziness, sensory impairment, neuropathy, drowsiness, gastroesophageal reflux, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, weakness, angioedema, anaphylactic reaction, vomiting, chronic malabsorption similar to intestinal disease, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness including orthostatic dizziness, palpitations, hypertension, low back pain, increased serum creatinine, diarrhea, pruritus, cough, epistaxis, upper respiratory infection, asthma, allergic reactions including angioedema, diabetes, headache, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy including myositis, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia and systemic symptoms in drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders including insomnia and nightmares, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory impairment, forgetfulness, amnestic syndrome, memory disorder, confusion, severe muscle weakness, ocular muscle weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is best kept at room temperature, between 1°C and 30°C, to maintain the medication's efficacy over time.

Appearance and packaging

Appearance

White or yellowish round film-coated tablets

Package unit

30 tablets/box [30 tablets (10 tablets/Alu-Alu) x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.